



Continuum mechanics and computational modeling of ocular tissues for in silico therapies


E. Friedmann, A. Drobny

Institute of Mathematics, University of Kassel, Germany
Prague 2024









- ▶ Geometry: The Virtual Human Eye
- ▶ A living system: modeling the physiology (flow and structures)
- ▶ The pathophysiology (glaucoma, Age-related Macular Degeneration, AMD)
- ▶ Modeling & Simulation of the treatment (stent, trabeculectomy, pharmacological models)
- ▶ Analyzing the treatment efficacy

Anatomy of the eye





- ▶ each component of the eye is represented by a suitable mathematical function
- ▶ the parameters of the functions are fitted to data
- ▶ data from imaging techniques: US, MRI, OCT

A model for the vitreus





$$X = R(\phi) \cos(\phi), Y = R(\phi) \sin(\phi) \cos(\varphi), Z = R(\phi) \sin(\phi) \sin(\varphi), R(\phi) = p_1 + p_2 \cos(\phi) + p_3 \cos(\phi)^3$$



natural lense: 2 hemiellipsoids





artificial lense: thin cylinder & haptics: 2 ellipsoid-sections





healthy iris $I := \{x, y, z \in \text{hemielipsoid} \mid z^2 + y^2 > R^2, x \in [a, b]\}$





pathological iris $I := M \setminus \{x, y, z \in \mathbb{R} \mid z^2 + y^2 = R_z^2, x \in [h - a_I + s, h + s]\}$










$$cb(x) = \begin{cases} a_1(x + 4.5)^2 + a_2 & \text{for } -5.5 \leq x \leq -4.6 \\ a_3(x + 3.5)^2 + a_4 & \text{for } -4.61 \leq x \leq -1.7 \\ a_5 \exp x + a_6 & \text{for } -1.7 \leq x \leq 3.66 \end{cases}$$



$$\text{eye}(x) = \begin{cases} \sqrt{bb^2 - \left(\frac{(x-4.2) \cdot bb}{aa}\right)^2} & \text{for } 8 \leq x \leq 15 \\ c_1(x - 5.2)^2 + c_2 & \text{for } -3 \leq x \leq 8 \\ c_3 \exp x + c_4 & \text{for } -5 \leq x \leq -3 \\ \sqrt{b^2 - \left(\frac{(x-4.2) \cdot b}{a}\right)^2} & \text{for } -8.8 \leq x < -5 \end{cases}$$





- ▶ elastic structures: cornea, sclera, lens
- ▶ viscoelastic vitreous (healthy case)
- ▶ flow: aqueous humour is produced in the ciliary body, fills the anterior chamber and leaves through trabecular meshwork
- ▶ flow: small fraction flows through the vitreous
- ▶ chemistry (signaling)
- ▶ exchange of molecules (diffusion, convection)

Fig. 48.2 www.nursekey.com/assessment-of-the-eye-and-vision-2,

[Sebag, Springer, 2014]

cornea, sclera & lens

- Conservation of momentum in Lagrangian framework

$$\hat{\rho}_s^0 \partial_t^2 \hat{u}_s - \widehat{\text{div}}(\hat{\Pi}) = \hat{\rho}_s^0 \hat{f}_s \quad \text{in } \hat{\Omega}_s, t \in I$$

with $\hat{\Pi} = \frac{\partial \hat{W}}{\partial \hat{F}}$, $\hat{J} = \det \hat{F}$, $\hat{F} := \hat{I} + \hat{\nabla} \hat{u}_s$, $\hat{C} = \hat{F}^T \hat{F}$ and a Neo-Hookean solid for cornea & sclera: [Simo et al. 1985, Grytz et al. 2014]

$$\hat{\Pi} = \mu \hat{J}^{-2/3} \left(\hat{F} - \frac{1}{3} \text{tr}(\hat{C}) \hat{F}^{-T} \right) + \kappa \ln \hat{J} \hat{F}^{-T}$$

lens: [Wilde 2011]

$$\hat{\Pi} = \mu \hat{J}^{-2/3} \left(\hat{F} - \frac{1}{3} \text{tr}(\hat{C}) \hat{F}^{-T} \right) + \kappa (\hat{J} - 1) \hat{J} \hat{F}^{-T}$$

- Mixed formulation

$$\hat{\rho}_s^0 \partial_t \hat{v}_s - \widehat{\text{div}}(\hat{\Pi}) = \hat{\rho}_s^0 \hat{f}_s \quad \text{in } \hat{\Omega}_s, t \in I$$

$$\partial_t \hat{u}_s - \hat{v}_s = 0 \quad \text{in } \hat{\Omega}_s, t \in I$$

+ Initial and boundary conditions (Dirichlet and Neumann b.c.)

model equations:

- ▶ steady Stokes equations in the anterior chamber
- ▶ Darcy model for the flow through the trabecular meshwork (TMW)

Parameter:


- ▶ volume of the anterior chamber $V = 0.16$ ml
- ▶ gravitation $f = (-g, 0, 0)$
- ▶ viscosity of the aqueous humor $\nu = 7 \cdot 10^{-7}$ Pa·s
- ▶ inflow (production rate in the ciliary body) $v_{\text{in}} = 2$ mm³/min
- ▶ permeability of the trabecular meshwork (TMW) $K = 0.778 \cdot 10^{-9}$ mm²
- ▶ outflow condition at TMW: episcleral pressure 1200 Pa = 9 mmHg
- ▶ pupil aperture $d = 3$ mm

$$\begin{aligned}-\nabla \cdot \mathbb{T}(u, p) &= f \\ \nabla \cdot u &= 0 \\ u &= u_{\text{in}}^{CB} \text{ on } \Gamma_{\text{in}} \\ u &= 0 \text{ on } \Gamma_{\text{ns}} \\ n \cdot \mathbb{T}(u, p) \cdot n &= p_0 \text{ on } \Gamma_{\text{out}} \\ n \cdot \mathbb{T}(u, p) \cdot \tau &= \tilde{\alpha} u \cdot \tau \text{ on } \Gamma_{\text{out}},\end{aligned}$$

with $\mathbb{T}(u, p) = 2\nu\mathbb{D}(u) - pl$, the normal vectors n , the tangential vectors τ ,
 $p_0 = \frac{1}{|\Omega_p|} \int_{\Omega_p} p(x) dx$ the pressure of the TM calculated via Darcy and $\tilde{\alpha}$ donates the friction constant

$$\begin{aligned}-\nabla \cdot \left(\frac{K}{\nu} \nabla p \right) &= f_2 \\ \frac{K}{\nu} \nabla p \cdot n &= 0 \text{ on } \Gamma_{\text{wall}} \\ \frac{K}{\nu} \nabla p \cdot n &= u_{\text{in}}^{TW} \cdot n \text{ on } \Gamma_{\text{in}} \\ p &= p_{\text{out}} \text{ on } \Gamma_{\text{out}},\end{aligned}$$


Stokes model: Taylor Hood Finite Elements



streamlines for the aqueous humor flow





Darcy model: Lagrange Finite Elements

DB: solution-sp.vtk



LOW: VOSSEY
Thu Nov 23 15:14:00 2017


trabecular meshwork



IOP=28.37 mmHg partly clogged TMW


IOP=23.17 mmHg (−18%) after intervention (trabeculectomy)

$d = 360 \mu\text{m}$, vaulting $v = 350 \mu\text{m}$, $K = 0.778 \cdot 10^{-9} \text{ mm}^2$, $\nu = 7 \cdot 10^{-7} \text{ Pa}\cdot\text{s}$



IOP: 10.09 mmHg for the healthy eye

IOP: 17.50 mmHg for the eye with pIOL.



- ▶ general balance equations:

$$\begin{aligned}\rho_f \partial_t v_f + \rho_f (v_f \cdot \nabla) v_f - \operatorname{div} \mathbb{T} &= \rho_f f && \text{in } \Omega_f, t \in I \\ \operatorname{div} v_f &= 0 && \text{in } \Omega_f, t \in I\end{aligned}$$

- ▶ pathological (liquified) vitreous: Navier-Stokes

$$\mathbb{T} = -p_f I + 2\rho_f \nu_f D(v_f), \quad D(v_f) := \frac{1}{2}(\nabla v_f + \nabla v_f^T)$$

- ▶ general balance equations:

$$\begin{aligned}\rho_f \partial_t v_f + \rho_f (v_f \cdot \nabla) v_f - \operatorname{div} \mathbb{T} &= \rho_f f & \text{in } \Omega_f, t \in I \\ \operatorname{div} v_f &= 0 & \text{in } \Omega_f, t \in I\end{aligned}$$

- ▶ pathological (liquified) vitreous: Navier-Stokes

$$\mathbb{T} = -p_f I + 2\rho_f \nu_f D(v_f), \quad D(v_f) := \frac{1}{2}(\nabla v_f + \nabla v_f^T)$$

- ▶ healthy vitreous: viscoelastic Burgers-type model [Tüma, Stein, Prusa, EF 2018], [Tram & Swindle-Reilly, 2018], [Sharif-Kashani et al. 2011]

$$\mathbb{T} = -p_f I + 2\rho_f \nu_f D(v_f) + \mu_1(B_1 - I) + \mu_2(B_2 - I) \text{ with}$$

$$\overset{\nabla}{B}_1 + \frac{\mu_1}{\nu_1}(B_1 - I) = 0, \quad \overset{\nabla}{B}_2 + \frac{\mu_2}{\nu_2}(B_2 - I) = 0 \text{ and}$$

$$\overset{\nabla}{B}_1 := \partial_t B_1 + (v_f \cdot \nabla) B_1 - (\nabla v_f) B_1 - B_1 (\nabla v_f)^T$$


- ▶ boundary conditions: parabolic inflow + no-slip condition at the lens
+ outflow: $\mathbb{T} n \cdot n = k_{\text{perm}} v \cdot n, \mathbb{T} n \cdot \tau = 0$

Disease: Age-related macular degeneration (AMD)

- ▶ results in vision loss due to abnormal blood vessel growth underneath the retina
- ▶ leading cause of irreversible blindness among the older generation
- ▶ affected around 6.2 million people globally (status 2015)
- ▶ the age-related changes that stimulate the pathology are incompletely understood
- ▶ measure of the severity of the disease: vascular endothelial growth factor (VEGF)

Disease: Age-related macular degeneration (AMD)

- ▶ results in vision loss due to abnormal blood vessel growth underneath the retina
- ▶ leading cause of irreversible blindness among the older generation
- ▶ affected around 6.2 million people globally (status 2015)
- ▶ the age-related changes that stimulate the pathology are incompletely understood
- ▶ measure of the severity of the disease: vascular endothelial growth factor (VEGF)



Treatment: Anti-VEGF intravitreal injections

- ▶ 0.05ml Eylea (Aflibercept) or Lucentis (Ranibizumab) every month at the beginning
- ▶ drug diffuses to the retina and effects there locally at the macula

- Convection-diffusion equation


$$\partial_t c + (v \cdot \nabla) c - D \Delta c = 0 \text{ in } \Omega_f, t \in I$$

- Underlying flow: Burgers-type or Navier-Stokes

- Boundary conditions:

$$\begin{aligned} -(D \nabla c) \cdot n &= 0 && \text{on } \Gamma_{\text{lens}} \\ -(D \nabla c) \cdot n + c(v \cdot n) &= p_0 c && \text{on } \Gamma_{\text{hyaloid}} \\ -(D \nabla c) \cdot n + c(v \cdot n) &= p_1 c && \text{on } \Gamma_{\text{retina}} \end{aligned}$$

- + initial conditions





Sketch of the two domains sliced in the middle

► Vitreous: System of convection-diffusion-reaction equations

► Retina: System of diffusion-reaction equations

► Reaction chain:

[Hutton-Smith et al. 2018]



► Drug: A, VEGF: V, drug-VEGF complex VA, drug-VEGF-drug complex AVA

- convection-diffusion equation + binding & dissociation mechanism

$$\frac{dc_{a_{vit}}}{dt} + \mathbf{v}_v \cdot \nabla c_{a_{vit}} - D_{a_{vit}} \Delta c_{a_{vit}} = (k_{off} c_{va_{vit}} - 2k_{on} c_{v_{vit}} c_{a_{vit}}) + (2k_{off} c_{ava_{vit}} - k_{on} c_{a_{vit}} c_{va_{vit}}) \quad \text{in } \Omega_v, t \in I$$

$$\frac{dc_{v_{vit}}}{dt} + \mathbf{v}_v \cdot \nabla c_{v_{vit}} - D_{v_{vit}} \Delta c_{v_{vit}} = (k_{off} c_{va_{vit}} - 2k_{on} c_{v_{vit}} c_{a_{vit}}) \quad \text{in } \Omega_v, t \in I$$

$$\frac{dc_{va_{vit}}}{dt} + \mathbf{v}_v \cdot \nabla c_{va_{vit}} - D_{va_{vit}} \Delta c_{va_{vit}} = -(k_{off} c_{va_{vit}} - 2k_{on} c_{v_{vit}} c_{a_{vit}}) + (2k_{off} c_{ava_{vit}} - k_{on} c_{a_{vit}} c_{va_{vit}}) \quad \text{in } \Omega_v, t \in I$$

$$\frac{dc_{ava_{vit}}}{dt} + \mathbf{v}_v \cdot \nabla c_{ava_{vit}} - D_{ava_{vit}} \Delta c_{ava_{vit}} = -(2k_{off} c_{ava_{vit}} - k_{on} c_{a_{vit}} c_{va_{vit}}) \quad \text{in } \Omega_v, t \in I.$$

- diffusion equation + binding & dissociation mechanism + VEGF production

$$\frac{dc_{a_{\text{ret}}}}{dt} - D_{a_{\text{ret}}} \Delta c_{a_{\text{ret}}} = (k_{\text{off}} c_{v_{\text{ret}}} - 2k_{\text{on}} c_{v_{\text{ret}}} c_{a_{\text{ret}}}) + (2k_{\text{off}} c_{a_{\text{va}_{\text{ret}}}} - k_{\text{on}} c_{a_{\text{ret}}} c_{v_{\text{ret}}}) \quad \text{in } \Omega_{\text{ret}}, t \in I$$

$$\frac{dc_{v_{\text{ret}}}}{dt} - D_{v_{\text{ret}}} \Delta c_{v_{\text{ret}}} = (k_{\text{off}} c_{v_{\text{ret}}} - 2k_{\text{on}} c_{v_{\text{ret}}} c_{a_{\text{ret}}}) + \frac{k_p}{V_{\text{ret}}} \quad \text{in } \Omega_{\text{ret}}, t \in I$$


$$\frac{dc_{v_{a_{\text{ret}}}}}{dt} - D_{v_{a_{\text{ret}}}} \Delta c_{v_{a_{\text{ret}}}} = -(k_{\text{off}} c_{v_{a_{\text{ret}}}} - 2k_{\text{on}} c_{v_{\text{ret}}} c_{a_{\text{ret}}}) + (2k_{\text{off}} c_{a_{\text{va}_{\text{ret}}}} - k_{\text{on}} c_{a_{\text{ret}}} c_{v_{\text{ret}}}) \quad \text{in } \Omega_{\text{ret}}, t \in I$$

$$\frac{dc_{a_{\text{va}_{\text{ret}}}}}{dt} - D_{a_{\text{va}_{\text{ret}}}} \Delta c_{a_{\text{va}_{\text{ret}}}} = -(2k_{\text{off}} c_{a_{\text{va}_{\text{ret}}}} - k_{\text{on}} c_{a_{\text{ret}}} c_{v_{\text{ret}}}) \quad \text{in } \Omega_{\text{ret}}, t \in I.$$

- Interface condition of the type:

$$\begin{aligned} -D \partial_{n_{\text{vit}}} c_{j_{\text{vit}}} &= p_{\text{ILM}} (c_{j_{\text{vit}}} - c_{j_{\text{ret}}}) \quad \text{on } \Gamma_I \\ D \partial_{n_{\text{ret}}} c_{j_{\text{ret}}} &= D \partial_{n_{\text{vit}}} c_{j_{\text{vit}}} \quad \text{on } \Gamma_I \end{aligned}$$


- Boundary: Neumann condition



► The drug (anti-VEGF) distributes over time in the vitreous and slowly travels to the retina


► The VEGF concentration is higher in the retina than in the vitreous. Over time the VEGF in the retina decreases due to an increase of drug

- the gravitation is neglectable



- The amount of drug reaching the macula depends on the injection position and time
- best pair of injection angles: $\psi_{xy} = 50^\circ$, $\psi_z = 50^\circ$

- drug comparison: Lucentis (ranibizumab I, II) by Novartis vs Eylea (aflibercept) by Bayer



Conclusion:

- ▶ Our presented models describe the geometry & physiology of the human eye
- ▶ Personalized models for the geometry of the eye & vitreous (pathological & healthy)
- ▶ We can test products from industry (pIOL)
- ▶ Drug therapy: pharmacological models & FE simulation
- ▶ Comparison of different drugs, their efficacy and different injection positions

Acknowledgement: Financed by Klaus Tschira Foundation, Project No.00.265.2015 and BiTWerk, University of Kassel

Thank you for your attention!